On 13 September 2024, Celltrion announced it has won the contract to supply Herzuma® (trastuzumab), biosimilar to Roche’s Herceptin®, to the Brazilian Federal Government to the end of 2025. Celltrion will supply 660,000 vials of the biosimilar during the fifth consecutive year that it has held the government contract. It claims that Herzuma® is the most prescribed trastuzumab drug in Brazil and accounts for more than 50% of the market annually.
Celltrion also reports that it recently succeeded in winning the bid to supply Remsima® (infliximab), biosimilar to J&J’s Remicade®, to the Brazilian Federal Government for the third consecutive year. Last month, it was asked to supply 25% more vials of the drug than originally contracted.
This follows Celltrion’s recent tender successes regarding Remsima® and Herzuma® in Peru (May 2024) and Remsima SC® in Denmark (April 2024), Norway (February 2024) and Sicily (January 2024). In February 2024, Celltrion also secured a series of tenders in Peru to supply Herzuma® (trastuzumab biosimilar), Truxima® (rituximab biosimilar) and Yuflyma® (adalimumab biosimilar). In June 2024, Celltrion successfully applied to be the exclusive supplier of Remsima®, Herzuma® and Vegzelma® (bevacizumab biosimilar) to France’s largest pharmaceutical procurement group (Union des Hopitaux pour les Achats (UniHA)), until 2027.